Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 7/2023

Open Access 07-08-2023 | Peritoneal Dialysis | Systematic Reviews

Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility

Authors: Chau Wei Ling, Kamal Sud, Rahul Patel, Gregory Peterson, Troy Wanandy, Siang Fei Yeoh, Connie Van, Ronald Castelino

Published in: Journal of Nephrology | Issue 7/2023

Login to get access

Abstract

Background

This systematic review summarises the stability of less commonly prescribed antibiotics in different peritoneal dialysis solutions that could be used for culture-directed therapy of peritonitis, which would be especially useful in regions with a high prevalence of multidrug antibiotic-resistant strains.

Methods

A literature search of Medline, Scopus, Embase and Google Scholar for articles published from inception to 25 January, 2023 was conducted. Only antibiotic stability studies conducted in vitro and not recently reviewed by So et al. were included. The main outcomes were chemical, physical, antimicrobial and microbial stability. This protocol was registered in PROSPERO (registration number CRD42023393366).

Results

We screened 1254 abstracts, and 28 articles were included in the study. In addition to those discussed in a recent systematic review (So et al., Clin Kidney J 15(6):1071–1078, 2022), we identified 18 antimicrobial agents. Of these, 9 have intraperitoneal dosing recommendations in the recent International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines, and 7 of the 9 had stability data applicable to clinical practice. They were cefotaxime, ceftriaxone, daptomycin, ofloxacin, and teicoplanin in glucose-based solutions, tobramycin in Extraneal solution only and fosfomycin in Extraneal, Nutrineal, Physioneal 1.36% and 2.27% glucose solutions.

Conclusions

Physicochemical stability has not been demonstrated for all antibiotics with intraperitoneal dosing recommendations in the ISPD peritonitis guidelines. Further studies are required to determine the stability of antibiotics, especially in icodextrin-based and low-glucose degradation products, pH-neutral solutions.

Graphical abstract

Appendix
Available only for authorised users
Footnotes
1
Unable to contact the corresponding author of Tobudic et al. to verify the type of anidulafungin formulation used in the study.
 
2
Daptomycin’s final concentration after mixing PD solutions from the two compartments (glucose and non-glucose solutions) in Balance 1.5% glucose solutions before warming to 37 °C on a heating plate.
 
3
Final concentration will be 2 mg/L after mixing solutions from the non-glucose and glucose compartments together.
 
Literature
1.
Davenport A (2009) Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002–2003. Perit Dial Int 29(3):297–302PubMed
2.
Davies SJ, Bryan J, Phillips L, Russell GI (1996) Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transpl 11(3):498–506
3.
Tian Y, Xie X, Xiang S, Yang X, Zhang X, Shou Z et al (2016) Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study. Medicine (Baltimore) 95(49):e5569PubMed
4.
Li PK-T, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T et al (2022) ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 42(2):110–153PubMed
5.
So SWY, Chen L, Woo AYH, Ng DMH, Wong JKW, Chow KM et al (2022) Stability and compatibility of antibiotics in peritoneal dialysis solutions. Clin Kidney J 15(6):1071–1078PubMedPubMedCentral
6.
7.
Trissel LA (1983) Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm 40(7):1159–1160PubMed
8.
Hecq J-D, Bihin B, Jamart J, Galanti L (2017) Criteria for judging the quality of a publication on physicochemical stability of ready to use injectable drugs. Pharm Technol Hosp Pharm 2(2):79–84
9.
Albin H, Ragnaud JM, Demotes-Mainard F, Vinçon G, Couzineau M, Wone C (1986) Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 31(4):479–483PubMed
10.
Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C (1985) Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 38(3):285–289PubMed
11.
Lam MF, Tang BSF, Tse KC, Chan TM, Lai KN (2008) Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis. Perit Dial Int 28(5):540–542PubMed
12.
Silver SA, Harel Z, Perl J (2014) Practical considerations when prescribing icodextrin: a narrative review. Am J Nephrol 39(6):515–527PubMed
13.
Fischbach M, Terzic J, Chauvé S, Laugel V, Muller A, Haraldsson B (2004) Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrol Dial Transplant 19(4):925–932PubMed
14.
Usman M, Yeoungjee C, David WJ (2016) Peritoneal dialysis solutions. In: Robert E (ed) Some special problems in peritoneal dialysis. IntechOpen, Rijeka, p 2
15.
de Moraes TP, Olandoski M, Caramori JC, Martin LC, Fernandes N, Divino-Filho JC et al (2014) Novel predictors of peritonitis-related outcomes in the BRAZPD cohort. Perit Dial Int 34(2):179–187PubMedPubMedCentral
16.
Wiesholzer M, Winter A, Kussmann M, Zeitlinger M, Pichler P, Burgmann H et al (2017) Compatibility of meropenem with different commercial peritoneal dialysis solutions. Perit Dial Int 37(1):51–55PubMed
17.
Nguyen TT, Harmanjeet H, Wanandy T, Castelino RL, Sud K, Jose MD et al (2020) Pyridine levels in ceftazidime - peritoneal dialysis admixtures stored at body temperature. Perit Dial Int 40(2):171–178PubMed
18.
Deslandes G, Grégoire M, Bouquié R, Le Marec A, Allard S, Dailly E et al (2016) Stability and compatibility of antibiotics in peritoneal dialysis solutions applied to automated peritoneal dialysis in the pediatric population. Perit Dial Int 36(6):676–679PubMedPubMedCentral
19.
Mathew M, Gupta VD (1995) Stability of vancomycin hydrochloride solutions at various PH values as determined by high-performance liquid chromatography. Drug Dev Ind Pharm 21(2):257–264
20.
Enrique M, García-Montoya E, Miñarro M, Orriols A, Ticó JR, Suñé-Negre JM et al (2008) Application of an experimental design for the optimization and validation of a new HPLC method for the determination of vancomycin in an extemporaneous ophthalmic solution. J Chromatogr Sci 46(9):828–834PubMed
21.
Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR (2000) In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 44(6):1734–1736PubMedPubMedCentral
22.
Denning DW, Hanson LH, Perlman AM, Stevens DA (1992) In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 15(1):21–34PubMed
23.
Kariyawasam R, Challa P, Lau R, Boggild AK (2019) Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform. BMC Infect Dis 19(1):593PubMedPubMedCentral
24.
Salama S, Rotstein C (1997) Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipid. Can J Infect Dis 8(3):157–160PubMedPubMedCentral
25.
Faustino C, Pinheiro L (2020) Lipid systems for the delivery of amphotericin B in antifungal therapy. Pharmaceutics 12(1):29PubMedPubMedCentral
26.
Lau SY, Bee BC, Wong HS, Tan CS (2022) POS-694 the role of intraperitoneal amphotericin b in peritoneal dialysis-related fungal peritonitis-experience from a Malaysian centre. Kidney Int Rep 7(2):S298–S299
27.
Janknegt R, Paulissen A, Hooymans PM, Lohman JJ, Hermens WA (1990) Stability of amphotericin B in CAPD fluid. Perit Dial Int 10(4):287–289PubMed
28.
Manley HJ, Grabe DW, Norcross M, Cooperman TA, Stinchcomb AL, Hass M et al (2000) Stability of amphotericin B lipid complex (Abelcet) in peritoneal dialysis solutions. Perit Dial Int 20(1):87–90PubMed
29.
Saravolatz LD, Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “Gold Standard.” Clin Infect Dis 37(3):415–425
30.
Lestner JM, Hope W (2017) Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. In: Grayson ML, Crowe S, McCarthy JS, Cosgrove SE, Mouton JW, Hope W (eds) Chapter 148: anidulafungin, 7th edn. CRC Press, Cham, pp 2693–2706
31.
Tobudic S, Donath O, Vychytil A, Forstner C, Poeppl W, Burgmann H (2014) Stability of anidulafungin in two standard peritoneal dialysis fluids. Perit Dial Int 34(7):798–802PubMedPubMedCentral
32.
Peyro SPL, Albessard F, Gaillard C, Debruyne D, Ryckelynck JP, Coquerel A et al (2011) Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int 31(4):492–495
33.
Abdelghafour MM, Orbán Á, Deák Á, Lamch Ł, Frank É, Nagy R et al (2021) The effect of molecular weight on the solubility properties of biocompatible poly(ethylene succinate) polyester. Polymers (Basel) 13(16):2725PubMed
34.
Kuti EL, Kuti JL (2010) Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert Opin Drug Metab Toxicol 6(10):1287–1300PubMedPubMedCentral
35.
Ecalta 100 mg powder for concentrate for solution for infusion [prescribing information] Pfizer Limited, 2017. GlaxoSmithKline March.
36.
Brogden RN, Heel RC (1986) Aztreonam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 31(2):96–130PubMed
37.
Baba H (2017) Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. In: Grayson ML, Crowe S, McCarthy JS, Cosgrove SE, Mouton JW, Hope W (eds) Chapter 35: aztreonam and aztreonam-avibactam. CRC Press, Cham, pp 644–657
38.
Dratwa M, Glupczynski Y, Lameire N, Matthys D, Verschraegen G, Vaneechoutte M et al (1991) Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 13(Supplement_7):S645–S647PubMed
39.
Tobudic S, Prager I, Kussmann M, Obermüller M, Ursli M, Zeitlinger M et al (2020) Compatibility of aztreonam in four commercial peritoneal dialysis fluids. Sci Rep 10(1):1788PubMedPubMedCentral
40.
Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS (1983) Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 25(3):223–289PubMed
41.
Nath SK, Foster GA, Mandell LA, Rotstein C (1995) Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin. Can J Infect Dis 6(1):21–27PubMedPubMedCentral
42.
Minguela JI, de Pablos M, Castellanos T, Ruiz-de-Gauna R (2006) Peritonitis by Rhizobium radiobacter. Perit Dial Int 26(1):112PubMed
43.
Paap CM, Nahata MC (1990) Stability of cefotaxime in two peritoneal dialysis solutions. Am J Hosp Pharm 47(1):147–150PubMed
44.
Sewell DL, Golper TA, Brown SD, Nelson E, Knower M, Kimbrough RC (1983) Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am J Kidney Dis 3(3):209–212PubMed
45.
46.
Raffanti EF Jr, King JC (1974) Effect of pH on the stability of sodium ampicillin solutions. Am J Hosp Pharm 31(8):745–751PubMed
47.
Zaccardelli DS, Sanders Krcmarik C, Wolk R, Khalidi N (1990) Stability of imipenem and cilastatin sodium in total parenteral nutrient solution. J Parenter Enter Nutr 14(3):306–309
48.
Bigley FP, Forsyth RJ, Henley MW (1986) Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions. Am J Hosp Pharm 43(11):2803–2809PubMed
49.
Farooqi S, Naqvi BS, Gauhar S (2013) Stability study of antibiotic (Cefotaxime) in peritoneal dialysis solution with validation of analyzing method. Int J Pharm Pharm Sci 5(SUPPL 3):930–934
50.
Girón FF, Martín JMS, Gómez ER, Muñoz SC, Carmelo FG, Gómez IG et al (2017) Simultaneous Streptococcus canis and Pasteurella multocida peritonitis in a peritoneal dialysis patient. Perit Dial Int 37(4):483–484PubMed
51.
Mastrapasqua Sonia MMC, Calfunao D (2020) Pasteurella multocida peritonitis in a CAPD patient case report and a review of literature. Urol Nephrol Open Access J 8(4):99–100
52.
Poliquin PG, Lagacé-Wiens P, Verrelli M, Allen DW, Embil JM (2015) Pasteurella Species peritoneal dialysis-associated peritonitis: household pets as a risk factor. Can J Infect Dis Med Microbiol 26:389467
53.
Nahata MC (1991) Stability of ceftriaxone sodium in peritoneal dialysis solutions. DICP 25(7–8):741–742PubMed
54.
Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K (2007) In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51(3):826–830PubMed
55.
Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A (2010) Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54(2):846–851PubMed
56.
Titelman E, Karlsson IM, Ge Y, Giske CG (2011) In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70(1):137–141PubMed
57.
Harmanjeet H, Jani H, Zaidi STR, Wanandy T, Castelino RL, Sud K et al (2020) Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 40(5):470–476PubMed
58.
Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger PC et al (2002) Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 21(6):530PubMed
59.
60.
Tran MD, Sharley N, Ward M (2012) Stability of amoxycillin, clindamycin and meropenem in peritoneal dialysis solution. J Pharm Pract Res 42(3):218–222
61.
Kehoe WA, Weber JN, Fries DS (1988) The stability and compatibility of clindamycin phosphate and gentamicin sulfate alone and in combination in peritoneal dialysis solution. Perit Dial Int 8(2):153–154
62.
Seligman SJ (1973) In vitro susceptibility of methicillin-resistant Staphylococcus aureus to sulfamethoxazole and trimethoprim. J Infect Dis 128:543–544
63.
Aldridge KE, Gelfand MS, Schiro DD, Barg NL (1992) The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents. Diagn Microbiol Infect Dis 15(7):601–608PubMed
64.
Iravani A, Welty GS, Newton BR, Richard GA (1985) Effects of changes in pH, medium, and inoculum size on the in vitro activity of amifloxacin against urinary isolates of Staphylococcus saprophyticus and Escherichia coli. Antimicrob Agents Chemother 27(4):449–451PubMedPubMedCentral
65.
Jones C, Stevens DL, Ojo O (1987) Effect of minimal amounts of thymidine on activity of trimethoprim-sulfamethoxazole against Staphylococcus epidermidis. Antimicrob Agents Chemother 31(2):144–147PubMedPubMedCentral
66.
Holmes SE, Aldous S (1990) Stability of cotrimoxazole in peritoneal dialysis fluid. Perit Dial Int 10(2):157–160PubMed
67.
Bactrim 400/80 (Sulfamethoxazole 400mg/5mL and trimethoprim 80mg/5mL concentrate for solution for infusion)[Prescribing information], Pfizer Limited, 2022.
68.
Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP (2003) Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52(3):405–411PubMed
69.
Wootton M, MacGowan AP, Walsh TR (2006) Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 50(12):4195–4197PubMedPubMedCentral
70.
Parra MA, Campanero MA, Sádaba B, Irigoyen A, García-López L, Fernandez-Reyes MJ et al (2013) Effect of glucose concentration on the stability of daptomycin in peritoneal solutions. Perit Dial Int 33(4):458–461PubMedPubMedCentral
71.
Ramdas S, Yousaf F, Shastri MD, Wanandy T, Zaidi STR, Khandagale M et al (2016) Stability of daptomycin in peritoneal dialysis solutions packaged in dual-compartment infusion bags. Eur J Hosp Pharm 23(1):57–60PubMed
72.
Cubicin (daptomycin for injection), for Intravenous Use [prescribing information], Merck Sharp & Dohme LLC 2022.
73.
Cubicin RF (daptomycin for injection), for intravenous use [prescribing information], Merck Sharp & Dohme LLC 2017.
74.
Washington JA II, Wilson WR (1985) Erythromycin: a microbial and clinical perspective after 30 years of clinical use (first of two parts). Mayo Clin Proc 60(3):189–203PubMed
75.
Kane MP, Bailie GR, Moon DG, Siu I, Eisele G (1994) Stability of erythromycin lactobionate in peritoneal dialysate solutions. Perit Dial Int 14(1):79–81PubMed
76.
Kahan FM, Kahan JS, Cassidy PJ, Kropp H (1974) The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235(1):364–386PubMed
77.
Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15(11):e732–e739PubMed
78.
Kussmann M, Baumann A, Hauer S, Pichler P, Zeitlinger M, Wiesholzer M et al (2017) Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur J Clin Microbiol Infect Dis 36(11):2237–2242PubMedPubMedCentral
79.
Tobudic S, Matzneller P, Stoiser B, Wenisch JM, Zeitlinger M, Vychytil A et al (2012) Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob Agents Chemother 56(7):3992–3995PubMedPubMedCentral
80.
Fung HB, Kirschenbaum HL, Ojofeitimi BO (2001) Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 23(3):356–391PubMed
81.
Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA (2002) Linezolid stability in peritoneal dialysis solutions. Perit Dial Int 22(3):419–422PubMed
82.
Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M et al (2018) Compatibility of linezolid with commercial peritoneal dialysis solutions. Am J Health Syst Pharm 75(19):1467–1477PubMed
83.
Rolston KVI, Frisbee-Hume S, LeBlanc B, Streeter H, Hsi HD (2003) In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis 47(2):441–449PubMed
84.
Balfour JA, Lamb HM (2000) Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 59(1):115–139PubMed
85.
Nightingale CH (2000) Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20(3):245–256PubMed
86.
Bellido JL, Hernández FJ, Zufiaurre MN, García-Rodríguez JA (2000) In vitro activity of newer fluoroquinolones against Stenotrophomonas maltophilia. J Antimicrob Chemother 46(2):334–335PubMed
87.
Weiss K, Restieri C, De Carolis E, Laverdière M, Guay H (2000) Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 45(3):363–365PubMed
88.
Fernández-Varón E, Marín P, Espuny A, Villamayor L, Escudero E, Cárceles C (2006) Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36% and Dianeal PD1 3.86%). J Clin Pharm Ther 31(6):641–643PubMed
89.
Inman E, Kirsch, LE (1990) Inventor: an improved diluent formulation for daptomycin. European Patent Office, patent number 0386951 A2 USA. Date of publication of application: 12 September 1990. Accessed 13 July 2022
90.
Smythe MA, Rybak MJ (1989) Ofloxacin: a review. DICP 23(11):839–846PubMed
91.
Akpolat T (2009) Tuberculous peritonitis. Perit Dial Int 29(2):166–169
92.
Chan MK, Chau PY, Chan WW (1987) Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 28(6):277–280PubMed
93.
Battista C, Kane MP, Moon DG, Bailie GR (1995) Stability of ofloxacin in peritoneal dialysis solutions. Perit Dial Int 15(1):72–74PubMed
94.
Greenwood D (1988) Microbiological properties of teicoplanin. J Antimicrob Chemother 21(Suppl A):1–13PubMed
95.
Zacharopoulos GV, Manios GA, Papadakis M, Koumaki D, Maraki S, Kassotakis D et al (2023) Comparative activities of ampicillin and teicoplanin against Enterococcus faecalis isolates. BMC Microbiol 23(1):5PubMedPubMedCentral
96.
Kang Y, Chen Y, Zhang Z, Shen H, Zhou W, Wu C (2021) A case of peritoneal dialysis-associated peritonitis caused by Rhodococcus kroppenstedtii. BMC Infect Dis 21(1):565PubMedPubMedCentral
97.
Manduru M, Fariello A, White RL, Fox JL, Bosso JA (1996) Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution. Am J Health Syst Pharm 53(22):2731–2734PubMed
98.
Cunha BA (2007) Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother 19(2):232–233PubMed
99.
Cunha BA, McDermott B, Nausheen S (2007) Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 19(6):753–754PubMed
100.
Woodford N, Hill RL, Livermore DM (2007) In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 59(3):582–583PubMed
101.
Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J et al (1996) Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 40(9):2226–2228PubMedPubMedCentral
102.
Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J et al (2004) The glycylcyclines: a comparative review with the tetracyclines. Drugs 64(1):63–88PubMed
103.
Robiyanto R, Zaidi ST, Shastri MD, Castelino RL, Wanandy ST, Jose MD et al (2016) Stability of tigecycline in different types of peritoneal dialysis solutions. Perit Dial Int 36(4):410–414PubMedPubMedCentral
104.
Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS (1976) Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12(3):166–200PubMed
105.
Voges M, Faict D, Lechien G, Taminne M (2004) Stability of drug additives in peritoneal dialysis solutions in a new container. Perit Dial Int 24(6):590–595PubMed
106.
Pallotta KE, Elwell RJ, Nornoo AO, Manley HJ (2009) Stability of tobramycin and ceftazidime in icodextrin peritoneal dialysis solution. Perit Dial Int 29(1):52–57PubMed
107.
Mason NA, Johnson GE, O’Brien MA (1992) Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution. Am J Hosp Pharm 49(5):1139–1142PubMed
108.
Darwish IA (2006) Immunoassay methods and their applications in pharmaceutical analysis: basic methodology and recent advances. Int J Biomed Sci 2(3):217–235PubMedPubMedCentral
109.
Bastos ML, Hoffman DB (1974) Comparison of methods for detection of amphetamines, cocaine and metabolites. J Chromatogr Sci 12:269–280
110.
Fontana F, Torelli C, Giovanella S, Ligabue G, Alfano G, Gerritsen K et al (2020) Influence of dialysate temperature on creatinine peritoneal clearance in peritoneal dialysis patients: a randomized trial. BMC Nephrol 21(1):448PubMedPubMedCentral
111.
Welten AGA, Schalkwijk CG, Ter Wee PM, Meijer S, Van Den Born J, Beelen RJH (2003) Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 23(3):213–221PubMed
112.
Gozdzikiewicz J, Borawski J, Mysliwiec M (2009) Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost 15(1):92–97PubMed
113.
Kandel S, Zaidi STR, Wanandy ST, Ming LC, Castelino RL, Sud K et al (2018) Stability of ceftazidime and heparin in four different types of peritoneal dialysis solutions. Perit Dial Int 38(1):49–56PubMed
114.
Vaughan LM, Poon CY (1994) Stability of ceftazidime and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution. Ann Pharmacother 28(5):572–576PubMed
115.
Goodall KT, Chooi CC, Gallus AS (1980) Heparin stability: effects of diluent, heparin activity, container, and pH. J Clin Pathol 33(12):1206–1211PubMedPubMedCentral
116.
Patel RP, Narkowicz C, Jacobson GA (2009) Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J Pharm Sci 98(5):1700–1711PubMed
117.
Patel RP, Narkowicz C, Jacobson GA (2009) Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution. J Pharm Sci 98(3):1118–1128PubMed
118.
Capdevila JA, Gavaldà J, Fortea J, López P, Martin MT, Gomis X et al (2001) Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique. Clin Microbiol Infect 7(4):206–212PubMed
119.
De Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29(1):5–15PubMed
120.
Drake JM, Myre SA, Staneck JL, Draeger RW (1990) Antimicrobial activity of vancomycin, gentamicin, and tobramycin in peritoneal dialysis solution. Am J Hosp Pharm 47(7):1604–1606PubMed
121.
Walker SE, Iazzetta J, Law S, Biniecki K (2010) Stability of commonly used antibiotic solutions in an elastomeric infusion device. Can J Hosp Pharm 63(3):212–224PubMedPubMedCentral
122.
Martens HJ, De Goede PN, Van Loenen AC (1990) Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 47(2):369–373PubMed
123.
Tchiakpé L, Airaudo CB, Ould MA, Gayte-Sorbier A, Verdier M, Guerri J (1996) Stedim 6® and Clearflex®, two new multilayer materials for infusion containers. Comparative study of their compatibility with five drugs versus glass flasks and polyvinyl chloride bags. J Biomater Sci Polym Ed 7(3):199–206
124.
Hamada C, Hayashi K, Shou I, Inaba M, Ro Y, Io H et al (2005) Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Perit Dial Int 25(6):570–575PubMed
125.
Kowaluk EA, Roberts MS, Blackburn HD, Polack AE (1981) Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 38(9):1308–1314PubMed
126.
Vaux DL, Fidler F, Cumming G (2012) Replicates and repeats-what is the difference and is it significant? A brief discussion of statistics and experimental design. EMBO Rep 13(4):291–296PubMedPubMedCentral
Metadata
Title
Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility
Authors
Chau Wei Ling
Kamal Sud
Rahul Patel
Gregory Peterson
Troy Wanandy
Siang Fei Yeoh
Connie Van
Ronald Castelino
Publication date
07-08-2023
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 7/2023
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-023-01716-7

Other articles of this Issue 7/2023

Journal of Nephrology 7/2023 Go to the issue

Review

Dialysis after kidney transplant failure: how to deal with this daunting task?

Position papers and Guidelines

Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission

original Article

Development and validation of AI-based triage support algorithms for prevention of intradialytic hypotension

Research Letter

Effect of depression on health-related quality of life of renal patients according to the modality of renal replacement therapy

Research Letter

Recombinant Varicella Zoster vaccine in haemodialysis facilities: adherence and safety

Systematic Reviews

Effects of resistance training on patients with End-Stage Renal Disease: an umbrella review with meta-analysis of the pooled findings
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits